Abstract Library

#2262 Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

Introduction: Telotristat ethyl (TE) is a treatment for carcinoid syndrome (CS) diarrhea used in combination with somatostatin analog (SSA) therapy. In the Phase 3, randomized, placebo-controlled, double-blind TELESTAR and TELECAST studies, CS patients received TE at 250 mg 3 times per day (tid), 500 mg tid, or placebo tid in addition to SSAs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dillon J, Kulke M, Warner R, Bergsland E, Welin S,

Keywords: telotristat ethyl, somatostatin analogs, carcinoid syndrome,